Search | Clinical Trials Finder

Conditions: Glaucoma
Interventions: Travoprost 0.004%/timolol maleate 0.5% fixed combination; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug; Combination Product
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Inglewood, California • Newport Beach, California • Petaluma, California + 6 more

Conditions: Glaucoma, Open-Angle
Interventions: Travoprost Intraocular Implant, iStent infinite, Sham procedure; Drug · Device · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg; Device · Drug
Lead sponsor: Jonathon Myers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Angle-Closure, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Application Site Pigmentation Changes
Interventions: latanoprost, bimatoprost, travoprost; Drug
Lead sponsor: Summa Health System; Other
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Arlington Heights, Illinois • Akron, Ohio

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 40
States / cities: Bellflower, California • Inglewood, California • San Diego, California + 31 more

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Travatan; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Dry Eye Disease
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Glaucoma
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma and Ocular Hypertension
Interventions: Ophthalmic Insert; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glaucoma
Interventions: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 21
States / cities: Artesia, California • Inglewood, California • Newport Beach, California + 18 more

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dothan, Alabama

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Search by objective public record fields.

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

Travoprost Intraocular Implant + iStent Infinite

Assessing Ocular Surface Changes After Changing Glaucoma Medications

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

A Long-term Safety Study of Once-daily Travatan

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

Stop Retinal Ganglion Cell Dysfunction Study

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension